A Covid-19 antibody therapy used to treat President Donald Trump has been approved by the US drug regulator for people who are not yet hospitalised by the disease but are at high risk.
The green light for drugmaker Regeneron came after REGEN-COV2, a combination of two lab-made antibodies, was shown to reduce Covid-19-related hospitalisations or emergency room visits in patients with underlying conditions. "Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said Stephen Hahn, commissioner of the Food and Drug Administration (FDA).